Summary
Synopsys, Inc. (SNPS) reported strong financial performance for the fiscal year ended October 31, 2010. The company experienced a revenue increase of 2% year-over-year, reaching $1.38 billion, driven by growth in both upfront and time-based license revenues. Net income saw a significant increase of 41% to $237.1 million, largely attributable to a one-time tax benefit from an IRS settlement. The company maintained its recurring revenue business model, with over 90% of its revenue derived from time-based licenses, maintenance, and services, providing stability and predictability. Synopsys continued its strategy of growth through acquisitions, completing eight acquisitions in fiscal 2010 to expand its technology portfolio, particularly in IP and system-level solutions. The company ended the fiscal year with a robust cash position of $938.6 million and no outstanding borrowings under its credit facility. The report also highlights Synopsys's continued investment in research and development, essential for maintaining its competitive edge in the dynamic EDA market. Overall, the filing paints a picture of a financially sound company strategically investing in growth while navigating a competitive landscape.
Financial Highlights
54 data points| Revenue | $1.38B |
| Cost of Revenue | $281.09M |
| Gross Profit | $1.10B |
| R&D Expenses | $449.23M |
| Operating Expenses | $915.46M |
| Operating Income | $184.11M |
| Interest Expense | $251K |
| Net Income | $237.06M |
| EPS (Basic) | $1.60 |
| EPS (Diluted) | $1.56 |
| Shares Outstanding (Basic) | 148.01M |
| Shares Outstanding (Diluted) | 151.91M |
Key Highlights
- 1Total revenue increased by 2% to $1.38 billion in fiscal 2010, up from $1.36 billion in fiscal 2009.
- 2Net income rose by 41% to $237.1 million in fiscal 2010, primarily due to a $94.3 million tax benefit from an IRS settlement.
- 3The company successfully executed its acquisition strategy, completing eight acquisitions in fiscal 2010 to enhance its product offerings and market reach.
- 4Synopsys maintained a strong recurring revenue model, with over 90% of revenue coming from time-based licenses, maintenance, and services.
- 5Research and Development expenses increased by 7% to $449.2 million, reflecting continued investment in innovation.
- 6The company ended the fiscal year with a healthy cash and short-term investments balance of $938.6 million.
- 7Synopsys repurchased $184.7 million of its common stock during fiscal year 2010.